Notably, most coagulation factors (except for thefibrinogen level) or metabolic biomarkers (except for ALT and γ-glutamyltransferase, or GGT) did not show any substantial difference between the twogroups, implying that hypertension may not deteriorate the hematological indicesor coagulation profiles when patients were infected with SARS-CoV-2. This evidence concerns the gene GPT and hypertensive disorder.